Exhibit 1: Arcus's Coveted Anti-TIGIT Assets

1 September 2017

Taiho granted option to license exclusive rights to Asia to develop and commercialize cancer immunotherapies from the Arcus pipeline [See Deal]. Taiho to pay $35 m during first three years ($25 m up front) and can exercise option to any clinical-stage candidates over a five-year period. For any project it licenses, Arcus receives an option payment and up to $275 million per candidate for development, regulatory, and sales milestones, plus royalties.

27 May 2020

Gilead and Arcus enter into a 10-year partnership valued up to $2bln to co-develop and co-commercialize all current and future therapeutic product candidates in Arcus’s pipeline [See Deal], Deal includes option to license rights to the anti-TIGIT molecule, domvanalimab.

29 October 2020

Arcus announces collaboration with AstraZeneca to study domvanalimab in combination with AstraZeneca’s Imfinzi (durvalumab) in Phase III clinical trial in patients with unresectable Stage III NSCLC. Parties share costs of the trial and retain existing rights to their respective molecules. If Gilead exercises its option to co-develop and co-commercialize domvanalimab, the trial agreement would be part of the Gilead-Arcus joint development program. [See Deal]

18 November 2021

Gilead exercises options to three programs in Arcus’s clinical stage portfolio, including both anti-TIGIT molecules, domvanalimab and AB308.

30 November 2021

Taiho exercises option for domvanalimab and AB308 in Japan and certain other territories in Asia, excluding China.

21 December 2021

Gilead closes option to exercise three programs in Arcus’s clinical-stage portfolio and enters a new research collaboration with Arcus. Closing triggers option payments totalling $725 m from Gilead to Arcus.

Will Anti-TIGITs Prove Their Value in 2023?

More from In Vivo Archive

More from In Vivo